Sanofi/Lexicon Diabetes Drug Gets 8-8 Vote From FDA Panel
2019年1月18日 - 9:27AM
Dow Jones News
By Josh Beckerman
A diabetes drug being developed by Sanofi (SNY) and Lexicon
Pharmaceuticals Inc. (LXRX) received a tie vote from a U.S. Food
and Drug Administration advisory panel.
Before the 8-8 vote, Lexicon shares had been halted all day.
The FDA isn't required to follow the advice of such advisory
panels, but it generally does so. An FDA decision is expected by
March 22.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
January 17, 2019 19:12 ET (00:12 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
過去 株価チャート
から 3 2024 まで 4 2024
Sanofi (EU:SAN)
過去 株価チャート
から 4 2023 まで 4 2024